Solving the growing drug shortages
Until government price controls are lifted, the makers of generics will be unable to cover their production costs

Article Highlights

  • Until government price controls are lifted, generic drug makers won't be able to cover their costs

    Tweet This

  • Washington's policy prescription should be to unwind harmful regulation creating drug scarcities

    Tweet This

  • Obama's solution to #drug shortages ignores impact of price regulations

    Tweet This

Widening shortages of some essential injected drugs for chemotherapy and other treatments are leaving vulnerable patients without the medicines they need. So far, Washington's response will only reinforce the problem. Its policy prescription should instead be aimed at unwinding the regulations that created these scarcities in the first place.

The problems have affected mostly older sterile, injected (parenteral) drugs that are generic and typically sold at low prices for slim profit margins. More than 200 drugs are on the current shortage list kept by the American Society of Health-System Pharmacists. The shortages have caused patients to miss or delay chemotherapy or to get inferior antibiotics, anesthetics and intravenous nutrition.

President Obama blames the shortages on the paucity of manufacturers for these products. He says slim profit margins mean few firms want to make these drugs. This analysis ignores the significant impact that price regulations have had on the economics of parenteral-drug production. So does the president's solution.

On Oct. 31, Mr. Obama signed an executive order that, most notably, requires firms to give advance notice when they believe a drug may soon become scarce. But all this will do is institutionalize shortages by tipping off hospitals and market middlemen to buy up remaining supplies.

A dwindling number of competent manufacturers aren't the cause of the problem; they're its symptom. Branded drugs have only a single manufacturer, and they aren't facing the same problems.

"To fix this, we should lift existing price controls when it comes to critical injectable drugs that are generic."--Scott Gottlieb, M.D.

A handful of adept companies can supply these markets. Yet in recent years, the Food and Drug Administration (FDA) has gotten tough on snafus that have long plagued injectable generic drugs (such as sterility problems or metal shavings getting into solutions).

These are valid concerns, and with its vigilance heightened, the FDA has required manufacturers to undergo major plant renovations, suspend facilities or stop shipping goods from suspect production lines. Yet the FDA and the manufacturers often don't understand the drug-production processes well enough to detect the root cause of problems. Instead of calling for targeted fixes of troubled plants, the agency has often taken a very costly shotgun approach that requires upgrades virtually everywhere.

The bigger problem is that manufacturers can't easily raise prices to meet the resulting increased costs of production. A 2003 law fixes the price Medicare will pay for injected drugs to an "average sales price" that is at least six months old at any given time. This flawed concept means even if a generic firm raises its price to reflect increased production costs, the new price won't get paid by Medicare—meaning purchasers would be losing money for months at a time. The result is that generic prices can't rise to reflect changing demand or the need for bigger investments in manufacturing.

Branded drugs have faced similar production (and FDA) issues, and they are paid for under the same flawed scheme. But they have larger profit margins to offset the cost of plant upgrades. Among the generics makers—whose much smaller profits have been eroded away by production costs—more and more are choosing to exit product lines rather than invest money to meet steadily higher standards.

To fix this, we should lift existing price controls when it comes to critical injectable drugs that are generic. First, Medicare can be directed to ditch the flawed "average sales price" and reimburse manufacturers for these drugs according to the price that is paid by wholesalers on the open market and already reported to Medicare. Then generic firms could adjust prices to match rising production costs and meet demand.

These drugs should also get a holiday from other Medicaid price-control schemes that serve to distort market prices. Sen. Orrin Hatch, the ranking member of the Senate Finance Committee, is working on a legislative proposal to ease the regulatory and pricing burdens facing this market.

Better still, Medicare can move the reimbursement of these drugs from its price-controlled "Part B" scheme and into its "Part D" drug program, which already pays for the pills that senior citizens get from pharmacies. Part D is run like a real marketplace, where drug makers compete to sell their medicines to large purchasers.

Allowing generic injectables to be priced competitively would allow manufacturers to recoup the costs of production and bring shortages to an end.

Scott Gottlieb, M.D., is a resident fellow at AEI

Also Visit
AEIdeas Blog The American Magazine
About the Author


  • Scott Gottlieb, M.D., a practicing physician, has served in various capacities at the Food and Drug Administration, including senior adviser for medical technology; director of medical policy development; and, most recently, deputy commissioner for medical and scientific affairs. Dr. Gottlieb has also served as a senior policy adviser at the Centers for Medicare & Medicaid Services. 

    Click here to read Scott’s Medical Innovation blog.

    Follow Scott Gottlieb on Twitter.

  • Phone: 202.862.5885
  • Assistant Info

    Name: Kelly Funderburk
    Phone: 202.862.5920

What's new on AEI

image Getting it right: US national security policy and al Qaeda since 2011
image Net neutrality rundown: What the NPRM means for you
image The Schuette decision
image Snatching failure from victory in Afghanistan
AEI on Facebook
Events Calendar
  • 21
  • 22
  • 23
  • 24
  • 25
Wednesday, April 23, 2014 | 12:00 p.m. – 1:30 p.m.
Graduation day: How dads’ involvement impacts higher education success

Join a diverse group of panelists — including sociologists, education experts, and students — for a discussion of how public policy and culture can help families lay a firmer foundation for their children’s educational success, and of how the effects of paternal involvement vary by socioeconomic background.

Thursday, April 24, 2014 | 12:00 p.m. – 1:30 p.m.
Getting it right: A better strategy to defeat al Qaeda

This event will coincide with the release of a new report by AEI’s Mary Habeck, which analyzes why current national security policy is failing to stop the advancement of al Qaeda and its affiliates and what the US can do to develop a successful strategy to defeat this enemy.

Event Registration is Closed
Friday, April 25, 2014 | 9:15 a.m. – 1:15 p.m.
Obamacare’s rocky start and uncertain future

During this event, experts with many different views on the ACA will offer their predictions for the future.   

Event Registration is Closed
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.